A Drug Interaction Study of Boceprevir in Combination With Amlodipine or Diltiazem in Healthy Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE1

Study Classification

INTERVENTIONAL

Study Start Date

2012-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the pharmacokinetic interactions between the hepatitis C NS3 protease inhibitor boceprevir and the calcium channel blockers amlodipine and diltiazem in healthy volunteers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of ACE-Inhibition on Microvascular Function in Women With Assessed Microvascular Dysfunction

NCT02525081

Microvascular Angina

COMPLETED PHASE4

Pharmacokinetic Interaction Between Diltiazem and ACT-541468 in Healthy Subjects

NCT02526888

Healthy Subjects

COMPLETED PHASE1

Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel Inflammation

NCT00005928

Atherosclerosis Coronary Disease Vasculitis

COMPLETED PHASE2

Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome

NCT01952392

Acute Coronary Syndrome

COMPLETED

A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects

NCT03698513

Healthy Volunteers

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis C Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

boceprevir

boceprevir 800 mg tid

Group Type EXPERIMENTAL

Amlodipine

Intervention Type DRUG

amlodipine 2.5 mg QD

Diltiazem

Intervention Type DRUG

diltiazem 120 mg qd

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Amlodipine

amlodipine 2.5 mg QD

Intervention Type DRUG

Diltiazem

diltiazem 120 mg qd

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Able and willing to sign informed consent prior to any study-related activities.
2. Male or female subjects between 18 and 65 years of age inclusive.
3. Healthy, i.e. not suffering from a relevant acute or chronic illness.
4. Body Mass Index (BMI) of 17.5 to 31 kg/m2; and a total body weight \> 50 kg (110 lbs).
5. Acceptable medical history, physical examination, and 12-lead ECG at screening.
6. Acceptable laboratory values that indicate adequate baseline organ function at screening visit.
7. Willing to stop using any herbal or natural health products for 2 weeks prior to and during the study including: Grapefruit, grapefruit juice, St. John's Wort.
8. Willingness to abstain from alcohol use for 3 days prior to and during the study.
9. Female subject is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or is of childbearing potential and practicing one of the following methods of birth control:

* Condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD)
* A vasectomized partner
* Total abstinence from sexual intercourse

Exclusion Criteria

1. Have serological evidence of exposure to HIV or HCV.
2. Known allergies to any of the study medications.
3. Female subjects of childbearing potential who:

* Has a positive urine pregnancy test at screening.
* Is not willing to use a reliable method of barrier contraception during the study.
* Using only oral contraceptive as a birth control method.
* Is breastfeeding.
4. Inability to adhere to protocol.
5. Use of any medications (2 weeks prior to or during the study) other than occasional use of acetaminophen.
6. Female subjects using contraceptives that contain drospirenone.
7. Subjects that are currently smoking.
8. Subjects with hypertension or heart disease requiring medical treatment.
9. Any condition possibly affecting drug absorption (e.g., gastro intestinal disorder).
10. Patients may be excluded from the study for other reasons, at the investigator's discretion.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes